Acorda gains following Ampyra appeal arguments

Acorda Therapeutics Inc. (NASDAQ:ACOR) added over $117 million in market cap on Friday following oral arguments held Thursday in its appeal of a district court ruling invalidating four of five patents for multiple sclerosis drug Ampyra

Read the full 369 word article

User Sign In